APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sofosbuvir & Ledipasvir Compound Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Sofosbuvir & Ledipasvir Compound Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025195 pages

Choose your research edition.

Industry ResearchSofosbuvir & Ledipasvir Compound Drugs Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Sofosbuvir & Ledipasvir Compound Drugs Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Sofosbuvir & Ledipasvir Compound Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sofosbuvir & Ledipasvir Compound Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Sofosbuvir & Ledipasvir Compound Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Sofosbuvir & Ledipasvir Compound Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Sofosbuvir & Ledipasvir Compound Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Sofosbuvir & Ledipasvir Compound Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Sofosbuvir & Ledipasvir Compound Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Sofosbuvir & Ledipasvir Compound Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Sofosbuvir & Ledipasvir Compound Drugs include Biocon, Cipla, Dr Reddy’s Laboratories, Gilead Sciences, Hetero Drugs, Lupin Ltd, Natco Ltd, Sun Pharmaceutical Industries and Torrent Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Sofosbuvir & Ledipasvir Compound Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sofosbuvir & Ledipasvir Compound Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sofosbuvir & Ledipasvir Compound Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Sofosbuvir & Ledipasvir Compound Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Sofosbuvir & Ledipasvir Compound Drugs Segment by Company

Biocon

Cipla

Dr Reddy’s Laboratories

Gilead Sciences

Hetero Drugs

Lupin Ltd

Natco Ltd

Sun Pharmaceutical Industries

Torrent Pharmaceuticals

Zydus Cadila

Abbott

Sofosbuvir & Ledipasvir Compound Drugs Segment by Type

Bottled Packaging

Film Coated Packaging

Sofosbuvir & Ledipasvir Compound Drugs Segment by Application

Hepatitis C Virus (HCV) Genotype 4

Hepatitis C Virus (HCV) Genotype 3

Hepatitis C Virus (HCV) Genotype 1

Others

Sofosbuvir & Ledipasvir Compound Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sofosbuvir & Ledipasvir Compound Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sofosbuvir & Ledipasvir Compound Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sofosbuvir & Ledipasvir Compound Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Sofosbuvir & Ledipasvir Compound Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Sofosbuvir & Ledipasvir Compound Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Sofosbuvir & Ledipasvir Compound Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Sofosbuvir & Ledipasvir Compound Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Sofosbuvir & Ledipasvir Compound Drugs Industry Trends Table 2. Sofosbuvir & Ledipasvir Compound Drugs Industry Drivers Table 3. Sofosbuvir & Ledipasvir Compound Drugs Industry Opportunities and Challenges Table 4. Sofosbuvir & Ledipasvir Compound Drugs Industry Restraints Table 5. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Manufacturers (k pcs) & (2021-2026) Table 8. Global Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share by Manufacturers Table 9. Global Sofosbuvir & Ledipasvir Compound Drugs Average Sales Price (US$/pcs) of Manufacturers (2021-2026) Table 10. Global Sofosbuvir & Ledipasvir Compound Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Sofosbuvir & Ledipasvir Compound Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Sofosbuvir & Ledipasvir Compound Drugs Manufacturers, Product Type & Application Table 13. Global Sofosbuvir & Ledipasvir Compound Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Sofosbuvir & Ledipasvir Compound Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Bottled Packaging Table 17. Major Manufacturers of Film Coated Packaging Table 18. Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Type 2021 VS 2025 VS 2032 (k pcs) Table 19. Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Type (2021-2026) & (k pcs) Table 20. Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Type (2027-2032) & (k pcs) Table 21. Global Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share by Type (2021-2026) Table 22. Global Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share by Type (2027-2032) Table 23. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Type 2021 VS 2025 VS 2032 (k pcs) Table 24. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Type (2021-2026) & (k pcs) Table 25. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Type (2027-2032) & (k pcs) Table 26. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hepatitis C Virus (HCV) Genotype 4 Table 29. Major Manufacturers of Hepatitis C Virus (HCV) Genotype 3 Table 30. Major Manufacturers of Hepatitis C Virus (HCV) Genotype 1 Table 31. Major Manufacturers of Others Table 32. Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Application 2021 VS 2025 VS 2032 (k pcs) Table 33. Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Application (2021-2026) & (k pcs) Table 34. Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Application (2027-2032) & (k pcs) Table 35. Global Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share by Application (2021-2026) Table 36. Global Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share by Application (2027-2032) Table 37. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Application 2021 VS 2025 VS 2032 (k pcs) Table 38. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Application (2021-2026) & (k pcs) Table 39. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Application (2027-2032) & (k pcs) Table 40. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share by Application (2027-2032) Table 42. Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 43. Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Region (2021-2026) & (k pcs) Table 44. Global Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share by Region (2021-2026) Table 45. Global Sofosbuvir & Ledipasvir Compound Drugs Sales Forecasted by Region (2027-2032) & (k pcs) Table 46. Global Sofosbuvir & Ledipasvir Compound Drugs Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Sofosbuvir & Ledipasvir Compound Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 48. North America Sofosbuvir & Ledipasvir Compound Drugs Sales by Country (2021-2026) & (k pcs) Table 49. North America Sofosbuvir & Ledipasvir Compound Drugs Sales by Country (2027-2032) & (k pcs) Table 50. Europe Sofosbuvir & Ledipasvir Compound Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 51. Europe Sofosbuvir & Ledipasvir Compound Drugs Sales by Country (2021-2026) & (k pcs) Table 52. Europe Sofosbuvir & Ledipasvir Compound Drugs Sales by Country (2027-2032) & (k pcs) Table 53. Asia Pacific Sofosbuvir & Ledipasvir Compound Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 54. Asia Pacific Sofosbuvir & Ledipasvir Compound Drugs Sales by Country (2021-2026) & (k pcs) Table 55. Asia Pacific Sofosbuvir & Ledipasvir Compound Drugs Sales by Country (2027-2032) & (k pcs) Table 56. South America, Middle East and Africa Sofosbuvir & Ledipasvir Compound Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 57. South America, Middle East and Africa Sofosbuvir & Ledipasvir Compound Drugs Sales by Country (2021-2026) & (k pcs) Table 58. South America, Middle East and Africa Sofosbuvir & Ledipasvir Compound Drugs Sales by Country (2027-2032) & (k pcs) Table 59. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share by Region (2021-2026) Table 63. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share by Region (2027-2032) Table 64. Biocon Company Information Table 65. Biocon Business Overview Table 66. Biocon Sofosbuvir & Ledipasvir Compound Drugs Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Biocon Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio Table 68. Biocon Recent Development Table 69. Cipla Company Information Table 70. Cipla Business Overview Table 71. Cipla Sofosbuvir & Ledipasvir Compound Drugs Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Cipla Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio Table 73. Cipla Recent Development Table 74. Dr Reddy’s Laboratories Company Information Table 75. Dr Reddy’s Laboratories Business Overview Table 76. Dr Reddy’s Laboratories Sofosbuvir & Ledipasvir Compound Drugs Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Dr Reddy’s Laboratories Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio Table 78. Dr Reddy’s Laboratories Recent Development Table 79. Gilead Sciences Company Information Table 80. Gilead Sciences Business Overview Table 81. Gilead Sciences Sofosbuvir & Ledipasvir Compound Drugs Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Gilead Sciences Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio Table 83. Gilead Sciences Recent Development Table 84. Hetero Drugs Company Information Table 85. Hetero Drugs Business Overview Table 86. Hetero Drugs Sofosbuvir & Ledipasvir Compound Drugs Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Hetero Drugs Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio Table 88. Hetero Drugs Recent Development Table 89. Lupin Ltd Company Information Table 90. Lupin Ltd Business Overview Table 91. Lupin Ltd Sofosbuvir & Ledipasvir Compound Drugs Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Lupin Ltd Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio Table 93. Lupin Ltd Recent Development Table 94. Natco Ltd Company Information Table 95. Natco Ltd Business Overview Table 96. Natco Ltd Sofosbuvir & Ledipasvir Compound Drugs Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Natco Ltd Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio Table 98. Natco Ltd Recent Development Table 99. Sun Pharmaceutical Industries Company Information Table 100. Sun Pharmaceutical Industries Business Overview Table 101. Sun Pharmaceutical Industries Sofosbuvir & Ledipasvir Compound Drugs Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Sun Pharmaceutical Industries Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio Table 103. Sun Pharmaceutical Industries Recent Development Table 104. Torrent Pharmaceuticals Company Information Table 105. Torrent Pharmaceuticals Business Overview Table 106. Torrent Pharmaceuticals Sofosbuvir & Ledipasvir Compound Drugs Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Torrent Pharmaceuticals Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio Table 108. Torrent Pharmaceuticals Recent Development Table 109. Zydus Cadila Company Information Table 110. Zydus Cadila Business Overview Table 111. Zydus Cadila Sofosbuvir & Ledipasvir Compound Drugs Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Zydus Cadila Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio Table 113. Zydus Cadila Recent Development Table 114. Abbott Company Information Table 115. Abbott Business Overview Table 116. Abbott Sofosbuvir & Ledipasvir Compound Drugs Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Abbott Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio Table 118. Abbott Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Sofosbuvir & Ledipasvir Compound Drugs Distributors List Table 122. Sofosbuvir & Ledipasvir Compound Drugs Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Sofosbuvir & Ledipasvir Compound Drugs Product Image Figure 2. Global Sofosbuvir & Ledipasvir Compound Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sofosbuvir & Ledipasvir Compound Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Sofosbuvir & Ledipasvir Compound Drugs Sales (2021-2032) & (k pcs) Figure 5. Global Sofosbuvir & Ledipasvir Compound Drugs Average Price (US$/pcs) & (2021-2032) Figure 6. Global Top 5 and 10 Sofosbuvir & Ledipasvir Compound Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Bottled Packaging Image Figure 9. Film Coated Packaging Image Figure 10. Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 11. Global Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share by Type (2021-2032) Figure 13. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 14. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share by Type (2021-2032) Figure 16. Hepatitis C Virus (HCV) Genotype 4 Image Figure 17. Hepatitis C Virus (HCV) Genotype 3 Image Figure 18. Hepatitis C Virus (HCV) Genotype 1 Image Figure 19. Others Image Figure 20. Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 21. Global Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share by Application (2021-2032) Figure 23. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 24. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 27. North America Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share by Country (2021-2032) Figure 28. U.S. Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 29. Canada Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 30. Mexico Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 31. Europe Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 32. Europe Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share by Country (2021-2032) Figure 33. Germany Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 34. France Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 35. U.K. Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 36. Italy Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 37. Netherlands Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 38. Asia Pacific Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 39. Asia Pacific Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share by Country (2021-2032) Figure 40. China Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 41. Japan Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 42. South Korea Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 43. Southeast Asia Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 44. India Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 45. Australia Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 46. South America, Middle East and Africa Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 47. South America, Middle East and Africa Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share by Country (2021-2032) Figure 48. Brazil Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 49. South Africa Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 50. Saudi Arabia Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 51. Turkey Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 52. Argentina Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 53. UAE Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 54. Egypt Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 55. Chile Sofosbuvir & Ledipasvir Compound Drugs Sales and Growth Rate (2021-2032) & (k pcs) Figure 56. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Sofosbuvir & Ledipasvir Compound Drugs Revenue (2021-2032) & (US$ Million) Figure 59. North America Sofosbuvir & Ledipasvir Compound Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Sofosbuvir & Ledipasvir Compound Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Europe Sofosbuvir & Ledipasvir Compound Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Sofosbuvir & Ledipasvir Compound Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Sofosbuvir & Ledipasvir Compound Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Sofosbuvir & Ledipasvir Compound Drugs Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Sofosbuvir & Ledipasvir Compound Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Sofosbuvir & Ledipasvir Compound Drugs Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Sofosbuvir & Ledipasvir Compound Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Bottled Packaging
  • Film Coated Packaging
Applications
  • Hepatitis C Virus (HCV) Genotype 4
  • Hepatitis C Virus (HCV) Genotype 3
  • Hepatitis C Virus (HCV) Genotype 1
  • Others
Companies covered
  • Biocon
  • Cipla
  • Dr Reddy’s Laboratories
  • Gilead Sciences
  • Hetero Drugs
  • Lupin Ltd
  • Natco Ltd
  • Sun Pharmaceutical Industries
  • Torrent Pharmaceuticals
  • Zydus Cadila
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Sofosbuvir & Ledipasvir Compound Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Sofosbuvir & Ledipasvir Compound Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Sofosbuvir & Ledipasvir Compound Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Sofosbuvir & Ledipasvir Compound Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Sofosbuvir & Ledipasvir Compound Drugs Market Dynamics
  1. 2.1 Sofosbuvir & Ledipasvir Compound Drugs Industry Trends
  2. 2.2 Sofosbuvir & Ledipasvir Compound Drugs Industry Drivers
  3. 2.3 Sofosbuvir & Ledipasvir Compound Drugs Industry Opportunities and Challenges
  4. 2.4 Sofosbuvir & Ledipasvir Compound Drugs Industry Restraints
3 Sofosbuvir & Ledipasvir Compound Drugs Market by Manufacturers
  1. 3.1 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Sofosbuvir & Ledipasvir Compound Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Sofosbuvir & Ledipasvir Compound Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Sofosbuvir & Ledipasvir Compound Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Sofosbuvir & Ledipasvir Compound Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Sofosbuvir & Ledipasvir Compound Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Sofosbuvir & Ledipasvir Compound Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Sofosbuvir & Ledipasvir Compound Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Sofosbuvir & Ledipasvir Compound Drugs Tier 1, Tier 2, and Tier 3
4 Sofosbuvir & Ledipasvir Compound Drugs Market by Type
  1. 4.1 Sofosbuvir & Ledipasvir Compound Drugs Type Introduction
  2. 4.1.1 Bottled Packaging
  3. 4.1.2 Film Coated Packaging
  4. 4.2 Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Type
  5. 4.2.1 Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Type
  9. 4.3.1 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share by Type (2021-2032)
5 Sofosbuvir & Ledipasvir Compound Drugs Market by Application
  1. 5.1 Sofosbuvir & Ledipasvir Compound Drugs Application Introduction
  2. 5.1.1 Hepatitis C Virus (HCV) Genotype 4
  3. 5.1.2 Hepatitis C Virus (HCV) Genotype 3
  4. 5.1.3 Hepatitis C Virus (HCV) Genotype 1
  5. 5.1.4 Others
  6. 5.2 Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Application
  7. 5.2.1 Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Sofosbuvir & Ledipasvir Compound Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Application
  11. 5.3.1 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share by Application (2021-2032)
6 Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Region
  1. 6.1 Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Sofosbuvir & Ledipasvir Compound Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Sofosbuvir & Ledipasvir Compound Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Sofosbuvir & Ledipasvir Compound Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Sofosbuvir & Ledipasvir Compound Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Sofosbuvir & Ledipasvir Compound Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Sofosbuvir & Ledipasvir Compound Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Sofosbuvir & Ledipasvir Compound Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Sofosbuvir & Ledipasvir Compound Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Sofosbuvir & Ledipasvir Compound Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Sofosbuvir & Ledipasvir Compound Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Region
  1. 7.1 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Region
  2. 7.1.1 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Sofosbuvir & Ledipasvir Compound Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Sofosbuvir & Ledipasvir Compound Drugs Revenue (2021-2032)
  8. 7.2.2 North America Sofosbuvir & Ledipasvir Compound Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Sofosbuvir & Ledipasvir Compound Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Sofosbuvir & Ledipasvir Compound Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Sofosbuvir & Ledipasvir Compound Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Sofosbuvir & Ledipasvir Compound Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Sofosbuvir & Ledipasvir Compound Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Sofosbuvir & Ledipasvir Compound Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Biocon
  2. 8.1.1 Biocon Company Information
  3. 8.1.2 Biocon Business Overview
  4. 8.1.3 Biocon Sofosbuvir & Ledipasvir Compound Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biocon Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio
  6. 8.1.5 Biocon Recent Developments
  7. 8.2 Cipla
  8. 8.2.1 Cipla Company Information
  9. 8.2.2 Cipla Business Overview
  10. 8.2.3 Cipla Sofosbuvir & Ledipasvir Compound Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cipla Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio
  12. 8.2.5 Cipla Recent Developments
  13. 8.3 Dr Reddy’s Laboratories
  14. 8.3.1 Dr Reddy’s Laboratories Company Information
  15. 8.3.2 Dr Reddy’s Laboratories Business Overview
  16. 8.3.3 Dr Reddy’s Laboratories Sofosbuvir & Ledipasvir Compound Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Dr Reddy’s Laboratories Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio
  18. 8.3.5 Dr Reddy’s Laboratories Recent Developments
  19. 8.4 Gilead Sciences
  20. 8.4.1 Gilead Sciences Company Information
  21. 8.4.2 Gilead Sciences Business Overview
  22. 8.4.3 Gilead Sciences Sofosbuvir & Ledipasvir Compound Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio
  24. 8.4.5 Gilead Sciences Recent Developments
  25. 8.5 Hetero Drugs
  26. 8.5.1 Hetero Drugs Company Information
  27. 8.5.2 Hetero Drugs Business Overview
  28. 8.5.3 Hetero Drugs Sofosbuvir & Ledipasvir Compound Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hetero Drugs Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio
  30. 8.5.5 Hetero Drugs Recent Developments
  31. 8.6 Lupin Ltd
  32. 8.6.1 Lupin Ltd Company Information
  33. 8.6.2 Lupin Ltd Business Overview
  34. 8.6.3 Lupin Ltd Sofosbuvir & Ledipasvir Compound Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lupin Ltd Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio
  36. 8.6.5 Lupin Ltd Recent Developments
  37. 8.7 Natco Ltd
  38. 8.7.1 Natco Ltd Company Information
  39. 8.7.2 Natco Ltd Business Overview
  40. 8.7.3 Natco Ltd Sofosbuvir & Ledipasvir Compound Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Natco Ltd Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio
  42. 8.7.5 Natco Ltd Recent Developments
  43. 8.8 Sun Pharmaceutical Industries
  44. 8.8.1 Sun Pharmaceutical Industries Company Information
  45. 8.8.2 Sun Pharmaceutical Industries Business Overview
  46. 8.8.3 Sun Pharmaceutical Industries Sofosbuvir & Ledipasvir Compound Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sun Pharmaceutical Industries Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio
  48. 8.8.5 Sun Pharmaceutical Industries Recent Developments
  49. 8.9 Torrent Pharmaceuticals
  50. 8.9.1 Torrent Pharmaceuticals Company Information
  51. 8.9.2 Torrent Pharmaceuticals Business Overview
  52. 8.9.3 Torrent Pharmaceuticals Sofosbuvir & Ledipasvir Compound Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Torrent Pharmaceuticals Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio
  54. 8.9.5 Torrent Pharmaceuticals Recent Developments
  55. 8.10 Zydus Cadila
  56. 8.10.1 Zydus Cadila Company Information
  57. 8.10.2 Zydus Cadila Business Overview
  58. 8.10.3 Zydus Cadila Sofosbuvir & Ledipasvir Compound Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Zydus Cadila Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio
  60. 8.10.5 Zydus Cadila Recent Developments
  61. 8.11 Abbott
  62. 8.11.1 Abbott Company Information
  63. 8.11.2 Abbott Business Overview
  64. 8.11.3 Abbott Sofosbuvir & Ledipasvir Compound Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Abbott Sofosbuvir & Ledipasvir Compound Drugs Product Portfolio
  66. 8.11.5 Abbott Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Sofosbuvir & Ledipasvir Compound Drugs Value Chain Analysis
  2. 9.1.1 Sofosbuvir & Ledipasvir Compound Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Sofosbuvir & Ledipasvir Compound Drugs Production Mode & Process
  6. 9.2 Sofosbuvir & Ledipasvir Compound Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Sofosbuvir & Ledipasvir Compound Drugs Distributors
  9. 9.2.3 Sofosbuvir & Ledipasvir Compound Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst